RK-1355A and B, novel quinomycin derivatives isolated from a microbial metabolites fraction library based on NPPlot screening

Lim CL 1 , Nogawa T 2 , Uramoto M 3 , Okano A 2 , Hongo Y 4 , Nakamura T 4 Show all authors , Koshino H 4 , Takahashi S 5 , Ibrahim D 6 , Osada H 5

Affiliations 

  • 1 1] Antibiotics Laboratory, RIKEN, Saitama, Japan [2] Industrial Biotechnology Research Laboratory, School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia
  • 2 RIKEN Center for Sustainable Research Science, Saitama, Japan
  • 3 Antibiotics Laboratory, RIKEN, Saitama, Japan
  • 4 RIKEN Global Research Cluster, Saitama, Japan
  • 5 1] Antibiotics Laboratory, RIKEN, Saitama, Japan [2] RIKEN Center for Sustainable Research Science, Saitama, Japan
  • 6 Industrial Biotechnology Research Laboratory, School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia
J Antibiot (Tokyo), 2014 Apr;67(4):323-9.
PMID: 24496142 DOI: 10.1038/ja.2013.144

Abstract

Two novel quinomycin derivatives, RK-1355A (1) and B (2), and one known quinomycin derivative, UK-63,598 (3), were isolated from a microbial metabolites fraction library of Streptomyces sp. RK88-1355 based on Natural Products Plot screening. The structural elucidation of 1 and 2 was established through two-dimensional NMR and mass spectrometric measurements. They belong to a class of quinomycin antibiotics family having 3-hydroxyquinaldic acid and a sulfoxide moiety. They are the first examples for natural products as a quinoline type quinomycin having a sulfoxide on the intramolecular cross-linkage. They showed potent antiproliferative activities against various cancer cell lines and they were also found to exhibit moderate antibacterial activity.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications